Last reviewed 2026-05-25 · How we verify

Erlotinb

Vanderbilt-Ingram Cancer Center · Phase 2 active Small molecule ✓ Verified May 2026

Erlotinb is a Small molecule drug developed by Vanderbilt-Ingram Cancer Center. It is currently in Phase 2 development.

Erlotinib is a medication being studied in clinical trials for the treatment of pancreatic cancer. It is being investigated in combination with sorafenib in a clinical trial (NCT00837876) at the Vanderbilt-Ingram Cancer Center.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Erlotinb
Sponsor	Vanderbilt-Ingram Cancer Center
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Sorafenib and Erlotinib in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Erlotinb CI brief — competitive landscape report
Erlotinb updates RSS · CI watch RSS
Vanderbilt-Ingram Cancer Center portfolio CI

Frequently asked questions about Erlotinb

What is Erlotinb?

Erlotinb is a Small molecule drug developed by Vanderbilt-Ingram Cancer Center.

Who makes Erlotinb?

Erlotinb is developed by Vanderbilt-Ingram Cancer Center (see full Vanderbilt-Ingram Cancer Center pipeline at /company/vanderbilt-ingram-cancer-center).

What development phase is Erlotinb in?

Erlotinb is in Phase 2.

Manufacturer: Vanderbilt-Ingram Cancer Center — full pipeline
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing